| Followers | 122 |
| Posts | 12252 |
| Boards Moderated | 0 |
| Alias Born | 11/08/2021 |
Thursday, January 11, 2024 2:13:54 PM
When SoS articles start coming out, it means NWBO is gonna be quiet for a long time.
I disagree.
What FEMike is doing here is insinuating NWBO and Larry Smith are criminally colluding to release news on a timeline that would be beneficial to supporting the NWBO share price. FEMike provided no corroborating information. FEMike offered no discussion on this accusation. FEMike only made a single conclusory statement.
In Court these kind of statements, especially ones alleging criminal behavior, would, at best, get you laughed out of court and, at worst, have you facing an ethical tribunal for potential disciplinary action. Yet, on stock forums, this is a regular Thursday for the morally deprived hedge fund social media army.
I went back and looked at two years of Larry Smith articles. This is what I saw:
✅️1-10-24 Article about recent MAA submission and potential 1H ’24 DCVax-L approval in the UK
✅️2-2-23 Article on the recently released FDA guidance on use of contemporaneous external controls
✅️11-17-22 Article on the recently published JAMA Oncology DCVax-L article
✅️6-6-22 Article about recent Dr. Ashkan ASCO Presentation
✅️5-11-22 Article about recent NYAS presentation on DCVax-L
✅️1-26-22 Article about the recent MHRA GMP certification of Sawston
✅️1-21-22 Article addressing recent FDA statement on use of external controls
Just like any reporter that reports the news, Larry Smith seemed to release his articles shortly after NWBO related news events.
I find it interesting that every time Larry Smith posts an article the hedge fund social media army finds it necessary to take cheap shots at him and NWBO.
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
